People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.
The substantial weight loss achieved with weekly semaglutide 2.4 mg is maintained if people continue to take the medication for 2 years, show the STEP 5 results.
Lifestyle intervention proves “highly successful” in adults with diabetes aged 65 to 85 years, improving both metabolic and functional health, report researchers.